The United States Food and Drug Administration (USFDA) has concluded an inspection at Lupin’s Goa facility in India. The inspection was carried out from September 6, 2021 to September 18, 2021 and closed with seven observations.
The company is confident of addressing the observations satisfactorily and is committed to be compliant with Good Manufacturing Practice standards across all its facilities.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.